<DOC>
	<DOCNO>NCT00929578</DOCNO>
	<brief_summary>The objective study assess safety biologic activity intralesional injection fluphenazine adult subject psoriasis .</brief_summary>
	<brief_title>Fluphenazine Hydrochloride Psoriasis</brief_title>
	<detailed_description>This double-blind , placebo-controlled , bilateral , ascend dose study . In vitro , fluphenazine show suppress growth proliferate T-lymphocytes . Fluphenazine would expect also suppress growth proliferate T-lymphocytes psoriatic plaque .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Fluphenazine</mesh_term>
	<mesh_term>Fluphenazine depot</mesh_term>
	<mesh_term>Fluphenazine enanthate</mesh_term>
	<criteria>Adults 18 65 year age psoriasis , general good health determine Principal Investigator base upon result medical history , laboratory profile , physical examination Must symmetric target lesion 24 cm diameter side body ( e.g. , thigh ) baseline Target Lesion Score ( TLS ) 6 high ( scale 012 ) target Women eligible participate study meet one follow criterion : Women postmenopausal ( least one year ) , sterile , hysterectomized Women childbearing potential must undergo monthly pregnancy test study agree use two follow method contraception throughout study 60 day last dose study drug : Oral contraceptive Transdermal contraceptive Injectable implantable method Intrauterine device Barrier method ( diaphragm spermicide , condom spermicide ) ( Abstinence Tubal Ligation also consider form Birth control . ) Patient asymptomatic major ailment screen exam . Infliximab ( Remicade® ) alefacept ( Amevive® ) within past 6 month ( 24 week ) Etanercept ( Enbrel® ) , efalizumab ( Raptiva™ ) , adalimumab ( Humira® ) tumor necrosis factor ( TNF ) alpha inhibitor within past 3 month ( 12 week ) Other systemic psoriasis therapy ( e.g. , methotrexate , cyclosporine , acitretin ) oral psoralen ultraviolet A ( PUVA ) within past 4 week ultraviolet B ( UVB ) topical therapy ( overthecounter ( OTC ) moisturizers shampoo ) within past 2 week ( include topical corticosteroid , vitamin A D analogue ) exception betamethasone valerate lotion ( 0.01 % ) treatment scalp lesion , triamcinolone cream ( 0.1 % ) lesion least 3 inch away target lesion Receipt investigation agent within past 4 week Systemic corticosteroid therapy Inability understand consent comply protocol ( patient ask understand question ) Pregnancy , lactation , unwillingness use adequate birth control study Impaired hepatic function Known HIV/AIDS , hepatitis B/C Blood dyscrasia Epilepsy Tardive dyskinesia Excessive alcohol consumption ( drink two drink per day average men one drink per day average woman ) Use phenothiazine antipsychotic anticholinergic Current use selective serotonin reuptake inhibitor ( SSRI ) , tricyclic , norepinephrine reuptake inhibitor antidepressant use within 6 week begin study Concurrent use antiseizure drug , exception gabapentin treatment neuropathy Known allergy fluphenazine phenothiazine , sesame oil sesame seed Known allergy parabens , paraaminobenzoate ( PABA ) benzyl alcohol Clinically significant uncontrolled cardiovascular disease correct QT interval ( QTc ) &gt; 450 msec , evidence clinically significant dysrhythmia ECG Operator heavy machinery Pheochromocytoma Clinically significant mitral valve disease History breast cancer History seizure disorder Occupational exposure organophosphate insecticide Parkinson 's disease related movement disorder Screening Lab abnormality include : Serum Asparate transaminase ( AST ) Alanine transaminase ( ALT ) &gt; 2.5 upper limit normal Creatinine ≥ 1.6 mg/dL Bilirubin ≥ 1.5 mg/dL White blood cell ( WBC ) count &lt; 3 x 10^9 /L Platelets &lt; 100 x 10^9/L Hemoglobin &lt; 10 g/dL female &lt; 12g/dL male Glucose ≥ 200 mg/dL Fasting blood sugar ≥ 126 mg/dL Concurrent use drug list Appendix E protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>T-lymphocytes</keyword>
	<keyword>Fluphenazine</keyword>
</DOC>